Close Menu

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced the acquisition of a portfolio of six patents and applications related to tissue microarrays for an undisclosed amount.

Nuclea acquired the IP from Laurus Master Fund, a division of Laurus Capital Management. Clinomics Biosciences previously owned the IP and assigned it to Laurus, but since then, the patents have not been maintained, Nuclea said, adding that it plans to petition the US Patent and Trademark Office immediately to revive them.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.